Study Results Present Efficacy and Safety Findings from the PHIRST-1 Study of Patients with Pulmonary Arterial Hypertension Taking Tadalafil Tablets Once Daily

... should seek immediate medical attention. For full patient information and/or full prescribing information, visit ... and seek medical attention right away. For full patient information ...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

... few patients required treatment. For full prescribing information, please visit ... erythromycin, and phenytoin. (Please see full Prescribing Information for other potential drug ... For more detailed study information, please see full Prescribing Information. Disclaimer The ...

New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)

... When this percentage is extrapolated to the full US population aged 18 and over, approximately 9.8 ... Additional information about VYVANSE and full Prescribing Information, including the Medication ... . Additional information about ADDERALL XR and full Prescribing Information, including the Medication ...

Pistachios Offer Protective Benefits Against Heart Disease, Type II Diabetes and Obesity

... of mixed nuts and half portion of muffin; or 3) full portion of muffin. Each snack accounted for 450 ... with heart heath. The findings revealed that the full dose nut group had significantly reduced LDL and total cholesterol levels compared to the full dose muffin group, as well as a significant ...

Kensey Nash Announces IDE Submission for Cartilage Repair Device

... an important accomplishment towards achieving full commercialization of this proprietary product and ... blood products. The Company has also developed a full complement of specialized color-coded instruments ... for the third quarter of fiscal 2009 and the full year fiscal 2009. The Company has tried to ...

CHMP Recommends Approval in the European Union (EU) for New Options for Patients With Certain Primary Brain Tumors

... for adult patients with refractory AA in 1999 and full approval in March 2005 for refractory AA, ie, ... Regarding EU Labeling for TEMODAL full prescribing information for TEMODAL can be found ... in the first cycle, respectively. full prescribing information for TEMODAR can be found ...

More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies

... warfarin, erythromycin and phenytoin. (Please see full Prescribing Information for other potential drug ... For more detailed study information please see full Prescribing Information. About Tasigna ... with hepatic impairment. Please see full Prescribing Information. About Exjade ...

PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S.

... PLCSF) announced today that it has received full approval from the U.S. Food and Drug ... of PLC, said, "We are very pleased with the FDA's full approval to the Investigational Device Exemption ... under the CE Mark we received in late 2007. full FDA approval of the IDE supplement is another ...

Early Data Show Potential for Imatinib Mesylate Tablets to Treat Life-Threatening Form of Pulmonary Artery Disease

... warfarin, erythromycin and phenytoin. (Please see full Prescribing Information for other potential drug ... more detailed study information, please see full Prescribing Information. (**)For more detailed study information, please see full Prescribing Information. Disclaimer The ...

AstraZeneca Receives Six Months Pediatric Exclusivity for CASODEX(R) (bicalutamide) from the FDA

... for use alone or with other treatments. See full Prescribing Information under the section ... For more information about CASODEX, including full Prescribing Information please visit ... For more information about ZOLADEX, including full Prescribing Information for ZOLADEX 3.6 mg Depot ...

Anesiva Accelerates Its Transition to Specialty Pharma Pain Management Company

... updates on Zingo launch progress, announced the full enrollment of its Phase 3 Adlea clinical trials ... year and in 2009. The company anticipates that full automation of Zingo manufacturing will decrease ... procedures in children ages three to 18. For full Zingo prescribing information and other ...

GeoVax Reports Progress on Its AIDS Vaccine Technology

... virus). In Phase 1 trials, both 1/10th dose and full dose of the GeoVax vaccine elicited anti-HIV T-cells, whereas the full dose was required to elicit good frequencies of ... base of safety and immunogenicity data for the full dose of the GeoVax AIDS vaccine with a view to ...

FDA Files Application To Convert ONTAK(R) (Denileukin Diftitox) to Full Approval for Use in Cutaneous T-Cell Lymphoma (CTCL)

... convert an accelerated approval indication into full approval. It is based on a ... (see PRECAUTIONS, Laboratory Tests, in full prescribing information for CD25 expression ... Visual Loss For detailed safety information and full prescribing information about ONTAK (denileukin ...

Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration

... First Presentation of full Data Set from the TRIUMPH-1 Trial of Inhaled ... viable treatment options for patients along the full continuum of this life-threatening disease," said ... at the University of Michigan, presented the full data set from the TRIUMPH-1 study of ...

Baxter Presents Latest Clinical Trial Results of GAMMAGARD LIQUID Administered Subcutaneously

... Technology enabled administration of a full monthly dose via a single site to patients with ... the amount of enzyme required to enable a full monthly dose to be infused in a single site ... of Immune Globulin Intravenous (Human). For full prescribing information, please visit ....

Novavax Reports Fourth Quarter and 2007 Year-End Financial Results

... of certain milestones. Revenue for the full year of 2007 was $1.5 million as compared to $1.7 ... The increases in both the fourth quarter and full year of 2007 as compared to 2006 were due to ... year. General and administrative costs for the full year of 2007 were $14.0 million compared to $11.3 ...

GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results

... for the comparable period in 2006. For the full year of 2007, the Company recorded a net loss ... financial information is shown below. GeoVax's full set of audited financial statements are included ... 2006, is designed to evaluate results from full dose administration of GeoVax HIV/AIDS vaccines. ...

RADIESSE More Effective Than Restylane As Reported In a 60-Patient Clinical Trial

... than Restylane volume was required to reach full correction in this split-face trial comparative ... and at three months in order to achieve full correction. The paper published in the Journal of ... required significantly less material to achieve full correction, with an average total injection ...

European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection

... 2008, Gilead is not making any adjustments to the full year 2007 Product Revenue guidance provided on ... didanosine-associated adverse events. See full Prescribing Information for complete list of ... to update any such forward-looking statements. full U.S. prescribing information, including Boxed ...

Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe

... didanosine-associated adverse events. See U.S. full Prescribing Information for complete list of ... to update any such forward-looking statements. full U.S. prescribing information, including Boxed ... available at http://www.atripla.com . full U.S. prescribing information for SUSTIVA is ...

GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update

... 2006, is designed to evaluate results from full dose administration of GeoVax HIV/AIDS ... data indicates excellent safety in this full dose trial with immune response data from the ... immune responses) at both low (1/10th) dose and full doses. * GeoVax vaccines were well ...

Vanda Pharmaceuticals Reports Third Quarter 2007 Results

... Phase II Proof of Concept Trial; Updates full Year 2007 Financial Guidance ROCKVILLE, Md., ... 2006. FINANCIAL GUIDANCE Vanda is updating its full year 2007 financial guidance as a result ... of the VEC-162 trial in primary insomnia. full year financial results are now expected to show ...

Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months

... statistically significant findings even after a full year. Anti-Nicotine Antibody Levels Drive ... reduction in cigarettes smoked over the full 12 months compared to placebo (p * Using a ... which will drive continuous abstinence out to a full year, we know the relationship between the ...

Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting

... week one that were observed throughout the full treatment period. At endpoint, VYVANSE provided a ... years. Additional information about VYVANSE and full Prescribing Information are available at ... survey of adults aged 18 to 44, projected to the full U.S. adult population. ADHD is a neurobiological ...

Elekta Announces Clinical Start-Up of New Leksell Gamma Knife(R) Perfexion(TM) at UPMC

... September 28. Immediately, UPMC was able to make full use of the new system and the center now is treating on average three patients, with full course treatments, per day. Gamma Knife(R) ... the Leksell Gamma Knife. UPMC continues to use a full range of Elekta stereotactic systems including a ...

European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)

... didanosine-associated adverse events. See full Prescribing Information for complete list of ... which the Company incorporates by reference. full U.S. prescribing information for ATRIPLA is available at http://www.atripla.com . full U.S. prescribing information for SUSTIVA is ...

Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV

... didanosine-associated adverse events. See full Prescribing Information for complete list of ... update any such forward-looking statements. U.S. full prescribing information for ATRIPLA is available at http://www.ATRIPLA.com . U.S. full prescribing information for SUSTIVA is available ...

Aptivus(R) (tipranavir) Capsules Granted Full Approval by the U.S. FDA

... U.S. Food and Drug Administration (FDA) granted full (traditional) approval of Aptivus(R) (tipranavir) ... and had documented PI resistance. At the time of full approval, the studies examined treatment ... innovative therapies for HIV patients. The full approval of APTIVUS further demonstrates our ...

Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer

... and/or impaired hepatic/renal function. (For full information on dose modification see SPC.) ... cardiovascular risk.) Common: Chest pain. For full details of these and other side-effects, please ... Injection site reactions (mainly mild). For full details of these and other side-effects, please ...

GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference

... immune responses) at both low (1/10th) dose and full doses. -- GeoVax vaccines were well tolerated ... trial participants. -- 80% of both the low and full dose trial participants responded to the ... -- More volunteers had antibody responses to the full dose than to the 1/10th dose vaccine, whereas ...

Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)

... for this disease." Pharmion expects to present full study results at an upcoming medical meeting. ... in this press release will be confirmed upon full analysis of the results of the Vidaza Survival ... even if these topline results are confirmed upon full analysis of the study, we cannot guarantee that ...

ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review

... of a co- stimulatory signal required for full T-cell activation. About Juvenile Idiopathic ... tract infection, sore throat, and nausea. For full Prescribing Information, please visit ... of people treated with placebo. According to the full prescribing information, the most frequently ...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

... and CFO of Isis. Upcoming Key Milestones Report full data from a Phase 3 study evaluating mipomersen in homozygous Familial ... We have the technology, the expertise and the momentum to realize the full potential of antisense as a drug discovery technology," concluded Ms. ...

SIRO Clinpharm Completes Successful Implementation of Oracle Life Sciences Application Suite

... MUMBAI, India, Aug. 5 /PRNewswire/ -- SIRO Clinpharm, a global, full service Contract Research Organization (CRO) founded in India, today ... one of the leading global Clinical Research Organizations (CROs), offering full scope services, conducting clinical trials in the pharmaceutical, ...

Is Your Hair Taking a Break?

... a short growth phase, resulting in baby fine hairs that do not reach their full length or diameter. Fortunately, several treatment options are ... growth phase of hair -- providing more time for hair to grow out to its full density. "Minoxidil is a wonderful option for women with thinning ...

July 2009 Mayo Clinic Health Letter Highlights a Positive Outlook, Bell's Palsy and Heart Valve Repair

... care to confirm a diagnosis and start treatment, which can up the odds of full recovery. The disorder is often related to a viral infection. ... Lyme disease or diabetes. Treatment increases the likelihood of full recovery and may help shorten the recovery time. A doctor may prescribe a ...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

... Schwalm, President of Eisai Inc. "This application is one part of a full complement of clinical development programs we have committed for Dacogen ... and diarrhea (34 percent). Please visit www.dacogen.com for full prescribing information. About Eisai Corporation of North America ...

Procter & Gamble Pharmaceuticals Launches Asacol(R) HD (mesalamine) Delayed-Release Tablets

... HD. Please visit http://www.asacol.com/pdf/us-asacol.pdf for Asacol full Prescribing Information and http://www.AsacolHD.com for Asacol HD full Prescribing Information. About Procter & Gamble (NYSE: PG ) ...

Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder

... (five percent or greater) were headache, nausea, dizziness, and insomnia. full prescribing information for NUVIGIL is available at www.NUVIGIL.com . ... [C-II]. The company also markets numerous products internationally. full prescribing information on its U.S. products is available at ....

Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009

... been used by more than one million patients since its introduction. For full prescribing information, visit www.BYETTA.com . Important Safety ... about any side effect that is bothersome or does not go away. For full prescribing information, visit www.BYETTA.com . About Amylin and ...